Roche Bulks Up In NLRP3 With €380m Inflazome Buy
Irish Biotech A Pioneer In Inflammasomes
Having acquired Jecure Therapeutics and its preclinical portfolio of NLRP3 inhibitors just under two years ago, the Swiss giant has swooped in to buy Dublin-based Inflazome and expand its presence in a hot field of inflammatory research.
